2026-527250-39-00RecruitingPhase 1
A clinical trial of MK-3586 in healthy participants (MK-3586-001)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 24 Aug 2026
- Start date
- 7 Oct 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- EU CT number
- 2026-527250-39-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 68
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
A trial of MK-3586 in healthy participants. The record lists rheumatoid arthritis as the condition studied.
- Age
- 18 to 64 years
- Sex
- Women and men can both join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Gent | Gent | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.